By acquiring GRID AI, it has stepped directly into one of the most urgent races of the decade: making sure energy can keep pace with the accelerating appetite of artificial intelligence.
The company, once known for enzymes and patient trials, is now in the grid game, acquiring GRID AI in a deal that rewires its entire identity.
Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions
Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions
July 15, 2026
Hello Readers,
Entero Therapeutics (NASDAQ: ENTO) is stepping into the AI and data-center power arena through the acquisition of GRID AI, targeting behind-the-meter energy management and storage optimization as hyperscaler build-outs strain the grid.
The thesis: use AI-driven optimization to cut power costs and smooth load for mission-critical facilities where uptime and efficiency matter most.
ENTO is repositioning from a clinical-stage biotech to a grid-edge software and services contender focused on AI workloads, data-center energy consumption, and distributed storage. The near-term focus is execution, financing, and customer traction, with milestones around productization and initial deployments.
Together, these actions underpin the pivot while management pursues commercialization in a rapidly expanding market.
If ENTO converts the GRID AI acquisition into signed deployments with measurable power savings, the pivot could be meaningful. Near-term proof points include pilot wins, energy-cost reductions, and reference customers.
NASDAQ: ENTO
129.37M
-2.14
February 26, 2026